Ozempic to Mounjaro Conversion Chart (Safe, Evidence-Based Guide)

If you are switching from Ozempic (semaglutide) to Mounjaro (tirzepatide), the most important point is that there is no FDA-approved, milligram-for-milligram conversion between the two medicines. The numbers on the pens are not equivalent doses, and a higher number of milligrams does not mean that one product is simply a stronger version of the other.

A safe switch depends on why you are changing treatment, which Ozempic dose you have been tolerating, your blood-glucose goals, gastrointestinal side effects, other diabetes medicines, and your cardiovascular and kidney history. This guide explains what the current labels and clinical evidence do - and do not - support so you can discuss the transition with your prescriber.

Key takeaway: There is no validated Ozempic-to-Mounjaro conversion ratio. Current prescribing information gives a labeled starting and escalation schedule for each medicine, while limited switching studies describe specific protocols in selected patients. Those studies should not be treated as a universal dose-equivalence chart.

Is There an Ozempic to Mounjaro Conversion Chart?

Not in the sense most people mean by “conversion chart.” Neither the FDA prescribing information nor the American Diabetes Association Standards of Care provides a table that says, for example, that 1 mg of Ozempic equals 5 mg of Mounjaro.

Ozempic is a GLP-1 receptor agonist. Mounjaro activates both GIP and GLP-1 receptors. Because the molecules, receptor activity, dose ranges, pharmacology, and titration schedules differ, their milligram doses cannot be compared directly.

The table below is therefore a switching reference, not an equivalence chart. It shows what is known for common Ozempic doses without implying that a specific Mounjaro dose is “equal” to them.

Ozempic-to-Mounjaro Conversion Chart: Evidence-Based Interpretation

The practical message is simple: do not calculate a Mounjaro dose by multiplying or dividing your Ozempic dose. A prescriber should choose the starting point and titration plan.

How Ozempic and Mounjaro Dosing Differ

Ozempic injection dosing

The current Ozempic injection label starts semaglutide at 0.25 mg once weekly for 4 weeks, then increases to 0.5 mg once weekly. For additional glycemic control, the dose may be increased to 1 mg and then 2 mg after at least 4 weeks at each preceding dose. The maximum recommended dose is 2 mg once weekly. For adults with type 2 diabetes and chronic kidney disease, the label specifies a maintenance dose of 1 mg once weekly after the initial titration.

Mounjaro dosing

The August 2026 Mounjaro label recommends a starting dose of 2.5 mg once weekly. If additional glycemic control is needed, the dose may be increased in 2.5-mg increments after at least 4 weeks on the current dose, up to 15 mg once weekly in adults. This is Mounjaro’s own dosing framework; it is not based on the dose of semaglutide a patient used previously.

Both products are taken once weekly, but their available strengths and escalation schedules are different. That is another reason a direct milligram-to-milligram conversion is misleading.

What Does the Evidence Say About Switching Directly to Tirzepatide?

There is some human evidence on direct switching, but it is much narrower than an online conversion chart may suggest. A 2024 prospective study followed adults with type 2 diabetes who had been on stable doses of a GLP-1 receptor agonist for at least 3 months. Participants using semaglutide 0.5 mg, 1 mg, or 2 mg - as well as certain doses of liraglutide or dulaglutide - switched directly to tirzepatide 5 mg and were followed for 12 weeks.

On average, A1C and body weight improved during follow-up. Gastrointestinal adverse events occurred in 13.2% of participants, and 2% discontinued tirzepatide because of adverse events. The study is useful evidence that a direct 5-mg switch can be used in selected, GLP-1-experienced adults with type 2 diabetes under clinical supervision.

However, it does not prove that 5 mg of tirzepatide is “equivalent” to any particular Ozempic dose. It also should not be generalized automatically to people who are early in Ozempic titration, have active gastrointestinal side effects, are restarting after a long treatment gap, or have different clinical circumstances. Several study authors were employees or shareholders of Eli Lilly, which should also be considered when interpreting the evidence.

When Can You Start Mounjaro After Your Last Ozempic Dose?

Neither product label provides a dedicated Ozempic-to-Mounjaro switching schedule. The missed-dose instructions in each label are designed for missed doses of that same medication; they should not be repurposed as a conversion rule.

Because both injections are weekly, practical expert guidance commonly places the new weekly medicine around the next scheduled weekly dose rather than overlapping the two drugs. A 2024 practical review suggested starting a new weekly incretin medicine 7 days after discontinuing the previous weekly product. That is expert guidance, not an FDA-labeled conversion instruction.

Your prescriber may choose a different interval if you have ongoing nausea or vomiting, dehydration, hypoglycemia risk, a prolonged treatment interruption, or another reason to delay or modify the transition. Do not overlap or “catch up” doses unless your prescriber specifically tells you to do so.

Do You Have to Restart at the Lowest Mounjaro Dose?

The current Mounjaro prescribing information starts treatment at 2.5 mg once weekly. At the same time, the 2024 direct-switch study described above used tirzepatide 5 mg in selected adults who were already stable on GLP-1 therapy, including semaglutide.

These two facts are not contradictory: one is the labeled starting regimen, while the other is evidence from a specific clinical switching protocol. They do not create a universal rule that everyone switching from Ozempic should start at either 2.5 mg or 5 mg.

A clinician may weigh factors such as your current Ozempic dose and duration, how well you tolerate gastrointestinal effects, glucose and A1C levels, use of insulin or a sulfonylurea, time since the last injection, and the reason for switching. The safest article-level advice is therefore to avoid prescribing a starting dose based only on the number printed on the Ozempic pen.

Why Are People Switched From Ozempic to Mounjaro?

Common reasons include not meeting individualized glucose or weight goals, side effects, cost or insurance coverage, availability, patient preference, or a clinician’s decision that another treatment better matches the person’s overall diabetes plan.

The 2026 ADA Standards emphasize person-centered medication selection based on glycemic and weight goals, cardiovascular and kidney disease, other comorbidities, hypoglycemia risk, adverse effects, treatment burden, cost, and preferences. They also recommend reassessing the treatment plan regularly rather than changing therapy based on a single metric.

Indications also matter. Ozempic injection is FDA-approved to improve glycemic control in adults with type 2 diabetes, reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reduce certain kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease. As of August 2026, Mounjaro is also FDA-approved to reduce major cardiovascular events in adults with type 2 diabetes who are at high risk for those events, in addition to its glycemic-control indication. These indications overlap in some areas but are not identical, so the reason a medicine was prescribed should be part of the switching decision.

What to Monitor After Switching

Blood sugar and A1C

If you use Mounjaro for type 2 diabetes, your clinician may review home glucose or continuous glucose monitoring data during the transition and reassess A1C at an interval appropriate for your treatment plan. Monitoring is especially important if insulin or a sulfonylurea is also being used because the risk of hypoglycemia can increase when an incretin-based medicine is added or intensified.

Gastrointestinal symptoms and hydration

Nausea, diarrhea, vomiting, constipation, dyspepsia, and abdominal discomfort are among the common adverse effects of tirzepatide and semaglutide. Persistent vomiting or diarrhea can contribute to dehydration and acute kidney injury. Contact your clinician if symptoms are severe, persistent, or make it difficult to keep fluids down.

Weight and treatment goals

Weight changes can be useful to track, but a switch should not be judged only by the first few weeks on the scale. Dose titration, appetite changes, glycemic response, tolerability, and the broader reason for treatment all matter.

Eye symptoms and other warning signs

Rapid improvements in glucose can sometimes be associated with worsening diabetic retinopathy in people who already have retinopathy. Both labels also include warnings or precautions involving pancreatitis, gallbladder disease, severe gastrointestinal reactions, hypersensitivity, kidney injury related to volume depletion, and pulmonary aspiration during anesthesia or deep sedation. Tell your care team about planned procedures and seek medical attention for severe or concerning symptoms.

Important Safety Questions Before Switching

• Do you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)? Both medicines are contraindicated in these situations.

• Are you currently having severe nausea, vomiting, diarrhea, or symptoms of gastroparesis? The labels caution about severe gastrointestinal adverse reactions and do not recommend use in severe gastroparesis.

• Do you use insulin or a sulfonylurea? Your clinician may need to reassess medicines that can cause hypoglycemia.

• Do you have diabetic retinopathy, gallbladder disease, kidney problems, or a history of pancreatitis? These issues can affect monitoring and risk assessment.

• Do you use an oral hormonal contraceptive? Tirzepatide can reduce oral contraceptive exposure during periods of greatest gastric-emptying effect. The Mounjaro label advises switching to a non-oral contraceptive method or adding a barrier method for 4 weeks after initiation and for 4 weeks after each dose escalation.

• Are you pregnant, planning pregnancy, or breastfeeding? Discuss the timing and choice of treatment with your clinician before switching.

Disclaimer

Disclaimer: This website connects patients with licensed healthcare providers who can evaluate medical conditions and prescribe medications when appropriate. Some medications available through this service may be compounded drugs, which are customized formulations prepared by a pharmacy. The FDA does not conduct premarket review for compounded drugs to evaluate their safety, effectiveness, or quality. (See here: https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved). Individual results may vary, and these medications should only be used under the guidance of a qualified healthcare professional. The information in this article is for educational purposes only and should not be considered medical advice. Always consult your healthcare provider before starting any new treatment.